Carbidopa prices slightly decreased globally in August 2025 amid balanced market conditions. China remains the largest API exporter to Western markets. Key factors include pre-stocked inventories reducing immediate buying pressure, Germany's inflation rise to 2.2%, and flat US demand during the US-China trade agreement extension. Looking ahead, China's Golden Week and end-year demand may tighten supply, with price recovery expected by late 2025.?
Key Highlights:
-
The price of Carbidopa decreased marginally in August following a July rise.
-
China continues to be the largest exporter of Carbidopa APIs into Western markets.
-
Buyers have stocked up, lessening the need for prompt purchasing.
-
The rate of inflation in Germany crept up to x.xx, triggering prudent consumer spending.
-
US demand was flat during an extension of the US-China trade agreement.
-
China&#xx;s October Golden Week might lead to short-term supply tightening.
-
Short-term vision foresees market stabilization and potential price recovery towards the end of xxxx.
In August xxxx, the global Carbidopa market experienced a slight price fall following a price rise last month. This shows harmony between steady downstream demand and sufficient supply. China is still the biggest exporter of Carbidopa APIs to Western countries such as the USA and Germany. Most of the overseas buyers had pre-stocked their inventories in advance and thus had lower immediate buying, thus exerting downward pressure...
